Discover investment opportunities in Best Stocks To Buy Under $2 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Stocks To Buy Under $2 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Stocks To Buy Under $2 using our Smart AI Filter.
7 stocks found for "Best Stocks To Buy Under $2"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.50 | ±100.0% | -0.4 | 0.00% | |||
0.71 | ±56.0% | -26.5 | 0.00% | |||
1.56 | ±82.7% | -121.0 | 0.00% | |||
1.35 | ±100.0% | -3.2 | 0.00% | |||
1.88 | ±100.0% | -85.1 | 0.00% | |||
0.98 | ±77.6% | 5.4 | 0.00% | |||
1.11 | ±78.2% | -6.2 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
The average of price targets set by Wall Street analysts indicates a potential upside of 59.9% in Spire (SPIR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read moreWM Technology MAPS has maintained stability in its profitability and cash flow, showcasing a 3% sequential sales increase to $45.9 million for 2Q24, despite a 5% year-over-year decline.
Read moreQ: What factors make SOLO an attractive option under $2?
A: Some investors consider SOLO advantageous due to its focus on affordable electric vehicles in a market transitioning to greener transportation. However, developing a niche in a highly competitive industry presents challenges. Investors should assess SOLO's production and sales consistency in achieving growth.
Q: How does GSAT’s satellite communications business impact its investment appeal?
A: GSAT's involvement in the satellite communications sector offers potential opportunities with the increasing need for connectivity in underserved areas. Investors may consider factors like GSAT's partnership strength and technology innovation as influential to its long-term viability.
Q: Why could GLBS be considered a speculative investment?
A: GLBS operates in the volatile and cyclical dry bulk shipping industry, which can impact revenue stability. Investors often watch for changes in global trade volume and commodities demand, influencing large fluctuations in GLBS's business performance and stock price.
Q: What growth potential does XERS offer in the biotech space?
A: XERS, known for its innovative drug delivery systems, may draw investor interest due to its potential to address unmet needs in healthcare. Success depends on product regulatory approval and market adoption, and the biotech sector often carries higher risk and reward.
Q: What challenges does VCSA face as a low-cost footwear retailer?
A: VCSA competes in a crowded and price-sensitive footwear market where consumer preferences shift rapidly. Challenges include managing inventory efficiently and sustaining brand recognition amidst larger players. Economic downturns could also impact discretionary spending on its products.
Q: How can CDTX's focus on infectious disease treatment impact its stock price?
A: Investors looking at CDTX may be interested in its pipeline for treating fungal infections. Success relies on developing effective treatments and navigating clinical trials. However, the biotech sector’s inherent risk and need for significant funding could affect future performance.